• PDF: Delivered by email usually within 48 UK business hours.

Merrion Pharmaceuticals Plc (3MP) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:41

Merrion Pharmaceuticals Plc (3MP) - Pharmaceuticals & Healthcare Deals and Alliances Profile

Merrion Pharmaceuticals Plc (3MP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Merrion Pharmaceuticals Plc (Merrion) is a specialty pharmaceutical company engaged in developing oral dosage forms of drugs that have poor absorption. The company's proprietary and patented GIPET technology focuses on improving the bioavailability of drugs with poor absorption, by improving absorption in the gastrointestinal tract. Leveraging its patented drug delivery technologies, Merrion has established relationships with some of the leading pharmaceutical companies, such as Novo Nordisk A/S and Ferring Pharmaceuticals. Currently, the company is focused on advancing its product pipeline, which comprises Orazol (MER-101), a Phase III clinical product for the treatment of Bone Metastases; Almerol (MER-103), an oral bisphosphonate for the treatment of osteoporosis (Phase II); Acyline (MER-104), an oral oncology product for the treatment of prostate cancer (Phase I); and MER-102, an oral anticoagulant for the treatment of deep vein thrombosis (preclinical studies). The company operates through three subsidiaries, namely: Merrion Research III Limited, Merrion Pharmaceuticals LLC and Merrion Pharmaceuticals Ireland Limited. Merrion is headquartered in Dublin, Ireland.

Merrion Pharmaceuticals Plc (3MP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.
  • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details
    • Asset Purchase
    • Merrion Pharmaceuticals Acquires A Pharmaceutical Facility For $5 Million
    • Venture Financing
    • Merrion Pharmaceuticals Secures $10 Million In Venture Financing
    • Merrion Pharmaceuticals Secures $7.54 Million In Venture Financing
    • Partnerships
    • Merrion Pharmaceuticals Enters Into Research Agreement With Trinity College
    • Merrion Pharmaceuticals Enters Into Research Agreement With Hunter-Fleming
    • Licensing Agreements
    • Merrion Pharmaceuticals Enters Into Option Licensing Agreement With Novo Nordisk
    • Merrion Pharmaceuticals Enters Into An Option Licensing Agreement With Rebel Pharmaceuticals
    • Merrion Pharmaceuticals Enters Into Licensing Agreement With Novo Nordisk
    • Merrion Pharmaceuticals Enters Into Licensing Agreement With Novo Nordisk
    • Equity Offering
    • Merrion Completes Private Placement Of $0.86 Million
    • Merrion Pharmaceuticals Completes Initial Public Offering Of $10.7 Million
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
    • Recent Developments
    • Strategy And Business Planning
    • Oct 29, 2009: Merrion Opens New Facility At Citywest Business Campus, Dublin
    • Financial Announcements
    • Sep 03, 2010: Merrion Reports Preliminary H1 2010 Results
    • Mar 08, 2010: Merrion Reports Preliminary 2009 Results
    • Sep 12, 2008: Interim Results For The Six Months Ended 30 June 2008
    • Apr 24, 2008: Preliminary Results For The Year Ended 31 December 2007
    • Research And Development
    • Sep 14, 2009: Merrion Announces Commencement Of Second Feasibility Collaboration Program With Ferring Pharmaceuticals
    • Corporate Communications
    • May 14, 2010: Merrion Appoints Hing Kin Chan As Chief Business Officer
    • Feb 12, 2009: Merrion Announces Board Changes
    • Government and Public Interest
    • Jan 27, 2011: Merrion To Make Two Presentations At 15th Annual Drug Delivery Partnerships, Miami, Florida
    • Sep 15, 2010: Merrion Announces Participation At Roche Colorado Corporation Peptide Symposium 2010
    • Jul 29, 2010: Merrion's New Facility Receives Manufacturing License From Irish Medicines Board
    • Product News
    • Dec 07, 2009: Novo Nordisk Starts Phase 1 Trial With Oral Insulin Analogue
    • Jul 17, 2006: Merrion Announces Collaboration With Hunter-Fleming
    • Jul 13, 2005: Merrion Pharmaceuticals, Inc. Is Issued A United States Drug Delivery System Patent
    • May 31, 2009: Merrion Pharmaceuticals Plc Announces Positive Final Results On Key Phase Ii Orazol Study
    • May 15, 2009: Merrion Pharmaceuticals Plc Announces Preliminary Results On Phase Ii Orazol Study
    • May 07, 2010: Merrion Pharmaceuticals Is Issued A Key Us Patent For Orazol, Their Lead Product To Treat Bone Metastases Associated With Prostate, Breast And Other Cancers
    • May 07, 2010: Merrion Receives US Patent For Orazol
    • Mar 30, 2005: Merrion Pharmaceuticals, Inc. Announces The Companys Latest Oral Drug Delivery Patent
    • Mar 10, 2009: Merrion Pharmaceuticals Announces Commencement Of Dosing Of Orazol In Us Clinical Study
    • Mar 02, 2010: Merrion Pharmaceuticals Is Issued A Key United States Patent
    • Mar 02, 2010: Merrion Pharmaceuticals Receives New US patent
    • Feb 18, 2009: Merrion Ceo, John Lynch, Addresses Biobusiness Conference, Geneva, Switzerland
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 41
  • List of Tables
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2009
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Deals By Therapy Area, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Merrion Pharmaceuticals Acquires A Pharmaceutical Facility For $5 Million
    • Merrion Pharmaceuticals Secures $10 Million In Venture Financing
    • Merrion Pharmaceuticals Secures $7.54 Million In Venture Financing
    • Merrion Pharmaceuticals Enters Into Research Agreement With Trinity College
    • Merrion Pharmaceuticals Enters Into Research Agreement With Hunter-Fleming
    • Merrion Pharmaceuticals Enters Into Option Licensing Agreement With Novo Nordisk
    • Merrion Pharmaceuticals Enters Into An Option Licensing Agreement With Rebel Pharmaceuticals
    • Merrion Pharmaceuticals Enters Into Licensing Agreement With Novo Nordisk
    • Merrion Pharmaceuticals Enters Into Licensing Agreement With Novo Nordisk
    • Merrion Completes Private Placement Of $0.86 Million
    • Merrion Pharmaceuticals Completes Initial Public Offering Of $10.7 Million
    • Merrion Pharmaceuticals Plc, Key Employees
    • Merrion Pharmaceuticals Plc, Subsidiaries 29
  • List of Figures
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Merrion Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about Merrion Pharmaceuticals Plc (3MP) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha